Healthcare Economics and Cost of Illness in Progressive Supranuclear Palsy represents an important but often understudied aspect of the disease burden. Understanding the economic impact of PSP is crucial for healthcare policy, resource allocation, clinical trial design, and advocacy efforts. This page synthesizes the current evidence on direct medical costs, indirect costs, caregiver burden, and healthcare resource utilization in PSP.
Progressive supranuclear palsy imposes a substantial economic burden on patients, families, healthcare systems, and society. Unlike more common neurodegenerative diseases, PSP has received relatively limited attention in health economics research, despite its significant impact on functioning and quality of life.
The economic burden of PSP can be categorized into:
Patients with PSP utilize significant healthcare resources across multiple settings[1]:
| Resource Type | Annual Utilization | Notes |
|---|---|---|
| Hospital admissions | 1.2-2.8 per patient | Higher than PD patients |
| Emergency department visits | 2.5-4.0 per patient | Often for falls/injuries |
| Outpatient visits | 8-15 per patient | Neurology, PT, OT, speech |
| Physical therapy sessions | 24-52 per patient | For gait/balance training |
| Occupational therapy | 12-30 per patient | ADL adaptations |
| Speech therapy | 12-24 per patient | Dysphagia management |
Medication costs in PSP include[2]:
The diagnostic pathway for PSP involves[3]:
PSP affects patients typically in the 60-70 year age range, often during peak earning years[4]:
Informal caregiving represents a significant component of the economic burden[5]:
| Caregiving Aspect | Annual Value |
|---|---|
| Hours of care per week | 20-60 hours |
| Annual caregiver hours | 1,000-3,100 hours |
| Replacement cost value | $25,000-$75,000/year |
| Work reduction/cessation | 30-50% of caregivers |
Caregiving tasks in PSP include:
Studies estimate substantial total annual costs for PSP patients[6][7]:
| Cost Category | Annual Cost (USD) |
|---|---|
| Direct medical costs | $15,000-$35,000 |
| Direct non-medical costs | $5,000-$20,000 |
| Indirect costs | $25,000-$60,000 |
| Total annual cost | $45,000-$115,000 |
Costs increase significantly with disease progression:
The lifetime cost of PSP is substantial[8]:
When compared to other neurodegenerative conditions[9]:
| Disorder | Annual Cost per Patient | Relative to PSP |
|---|---|---|
| Parkinson's disease | $25,000-$50,000 | Baseline |
| PSP | $45,000-$115,000 | 1.5-2.5x higher |
| MSA | $35,000-$80,000 | 1.2-1.8x higher |
| CBS/CBD | $40,000-$90,000 | 1.2-2.0x higher |
| Alzheimer's disease | $50,000-$120,000 | Similar |
PSP costs are higher than Parkinson's disease due to:
Hospital admissions in PSP are often for[1:1]:
Average hospitalization costs: $8,000-$25,000 per admission
Readmission rates: 25-35% within 30 days
Patients with PSP often require[2:1]:
Nursing home costs: $70,000-$100,000 annually
Home modification costs: $5,000-$50,000 (grab bars, ramps, walk-in showers)
Costs vary significantly across healthcare systems and countries[4:1]:
| Country/Region | Annual Cost (USD) | Key Features |
|---|---|---|
| United States | $60,000-$115,000 | Highest costs, private insurance dominant |
| Germany | $40,000-$70,000 | Social health insurance system |
| United Kingdom | $35,000-$60,000 | NHS coverage |
| Sweden | $45,000-$75,000 | Universal coverage |
| Spain | $30,000-$55,000 | National health system |
Understanding PSP costs informs[10]:
Health economic data supports:
Economic burden analysis enables:
Beyond direct and indirect costs, PSP imposes significant intangible burdens[5:1]:
Quality of life decrements correlate with increased costs:
Emerging areas of research include[3:1]:
Martinez M, et al. Healthcare costs and resource utilization in progressive supranuclear palsy: a retrospective claims analysis. Neurology. 2024. ↩︎ ↩︎
Chen Y, et al. Economic burden of atypical parkinsonism in the United States. Movement Disorders. 2024. ↩︎ ↩︎
Johansson A, et al. Cost-of-illness studies in progressive supranuclear palsy: a systematic review. Journal of Neurology. 2023. ↩︎ ↩︎
Winter Y, et al. Quality of life and economic burden in atypical parkinsonian syndromes. Journal of Neural Transmission. 2021. ↩︎ ↩︎
Holm R, et al. Informal caregiver burden in progressive supranuclear palsy: a European multicenter study. Parkinsonism & Related Disorders. 2023. ↩︎ ↩︎
Wen MC, et al. Healthcare resource utilization and costs in PSP patients: a Medicare claims study. Journal of Alzheimer's Disease. 2022. ↩︎
Boehm M, et al. Long-term care costs and resource utilization in PSP. Value in Health. 2020. ↩︎
Pope C, et al. Direct and indirect costs of progressive supranuclear palsy in Germany. European Journal of Health Economics. 2022. ↩︎
Gupte M, et al. Economic analysis of parkinsonian disorders from a claims database. Journal of Medical Economics. 2019. ↩︎
Martin J, et al. Health economic considerations in progressive supranuclear palsy. Expert Review of Pharmacoeconomics & Outcomes Research. 2018. ↩︎